BioNTech SE (BNTX) shares surged 5.32% in pre-market trading on Tuesday, following the announcement of a major research and development partnership with the UK government. The company plans to invest up to £1 billion ($1.33 billion) over 10 years to expand its research operations in the UK, supported by a government grant of up to £129 million.
The deal includes plans to open two new research centers and establish a headquarters in London. BioNTech aims to accelerate clinical trials, expand research areas, and grow its artificial intelligence hub. This significant investment demonstrates the company's commitment to long-term growth and innovation in the biotech sector.
Adding to the positive sentiment, reports of rising Covid-19 cases in several Asian countries, including Singapore, Hong Kong, and Thailand, have sparked speculation about potential increased demand for vaccines. As a leading Covid-19 vaccine developer, BioNTech stands to benefit from any resurgence in global vaccine requirements. Investors appear optimistic about the company's prospects in both its expanded research initiatives and potential renewed demand for its core product.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。